Core Viewpoint - Sanofi's Tzield (teplizumab) has received approval from the National Medical Products Administration (NMPA) in China for use in children aged 8 and above and adults with stage 2 type 1 diabetes, aiming to delay progression to stage 3 diabetes [1] Group 1 - Teplizumab is a CD3-targeting monoclonal antibody that protects endogenous pancreatic function, allowing patients to delay the progression from stage 2 to stage 3 type 1 diabetes by nearly 3 years [1] - This approval marks a significant milestone for the product, following its status as the first prescription approved in Asia earlier in June [1] - The approval represents a breakthrough in the treatment of type 1 diabetes in China, shifting the approach from "passive treatment" to "active intervention" [1]